<html>
<head>
<title>Short Summary </title>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
</head>

<body bgcolor="#B6B6B6">
<table width="777" border="0" cellpadding="0" cellspacing="0" bgcolor="#2E5C5C" align="center">
  <tr> 
    <td height="64" valign="top" colspan="2"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="000000" align="center">
        <tr> 
          <td width="750" height="50" valign="middle"> 
            <div align="center"> 
              <p><img src="../Assets/HTNBAtitle.gif" width="430" height="50"></p>
            </div>
          </td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="26" width="54"></td>
    <td valign="top" width="723" height="26"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0">
        <tr> 
          <td width="723" height="37"><a href="SS_HTNandBA.html"><img src="../Assets/SS1.gif" width="165" height="37" align="baseline" name="Short_Summary" border="0"></a><a href="ACP_HTNandBA.html"><img src="../Assets/SS2.gif" width="142" height="37" name="ACP" border="0"></a><a href="CE_HTNandBA.html"><img src="../Assets/SS3.gif" width="140" height="37" name="Clinical_Evidence" border="0"></a><a href="JNC6_HTNandBA.html"><img src="../Assets/SS4.gif" width="77" height="37" name="JNC_VI" border="0"></a><a href="PM_HTNandBA.html"><img src="../Assets/SS5.gif" width="78" height="37" name="PubMed" border="0"></a><a href="VA_HTNandBA.html"><img src="../Assets/SS6.gif" width="121" height="37" border="0"></td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="44" width="54"></td>
    <td valign="top" height="44"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0">
        <tr> 
          <td width="723" height="38"><img src="../Assets/SSheader.gif" width="330" height="50" align="baseline"><img src="../Assets/SSheader2.gif" width="393" height="50" align="baseline"></td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="469" width="54"></td>
    <td valign="top"> 
      <table width="100%" height="555" border="0" cellpadding="0" cellspacing="0">
<tr> 
          <td width="746" height="545" valign="top" bgcolor="ebfbfe"> 
<div align="center"><font color="#B70000"><br>
              <br>
              Last Updated: November, 2001 </font><br>
              <ul>
                <LI> 
                  <div align="left"><FONT color=#660033 face="Verdana, Arial, Helvetica, sans-serif" 
  size=-1>In head to head comparison, therapy with beta blockers (atenolol, metoprolol 
                    and propanolol) had similar cardiovascular outcomes (CAD, 
                    stroke and total CV events- stroke, CAD, CHF and other significant 
                    events -ruptured aneurysm) and mortality as compared thiazides. 
                    (<a 
  href="PM_HTNandBA.html#Wright">Wright 1999</a>) </FONT> </div>

                <LI> 
                  <div align="left"><font color=#660033 face="Verdana, Arial, Helvetica, sans-serif" 
  size=-1>First line therapy with beta blockers reduced risk of stroke (RR 0.71 
                    CI 0.59-0.86) and congestive heart failure (RR 0.58 CI 0.40-0.84) 
                    as compared to placebo. (<a 
  href="PM_HTNandBA.html#Psaty">Psaty 1997</a>)</font> </div>

                <LI> 
                  <div align="left"><FONT color=#660033 face="Verdana, Arial, Helvetica, sans-serif" 
  size=-1>First line therapy with beta adrenergic receptor antagonists as compared 
                    to placebo had no effect on morbidity or mortality of patients 
                    with primary hypertension. (<A 
  href="file:///W:/ATHENADSS/doc/ATHENA/Original%20papers/Hypertension%20and%20Beta%20Adrenergic%20Receptor%20Antagonist_OP.html#Wright">Wright 
                    1999</A>) </FONT> </div>
                <LI> 
                  <div align="left"><FONT color=#660033 face="Verdana, Arial, Helvetica, sans-serif" 
  size=-1>Tolerance and quality of life with beta adrenergic receptor antagonists 
                    and diuretics tended to be more favorable than with calcium 
                    channel blockers or ACE inhibitors. (<a 
  href="PM_HTNandBA.html#Wright">Wright 1999</a>) </FONT> </div>

                <LI> 
                  <div align="left"><FONT color=#660033 face="Verdana, Arial, Helvetica, sans-serif" 
  size=-1>First line therapy with beta blockers in patients &gt;60 years reduced 
                    the odds for cerebrovascular events (OR 0.75; 95% CI 0.57-0.98), 
                    but was ineffective in preventing coronary artery disease, 
                    cardiovascular mortality and all cause mortality. (<A 
  href="PM_HTNandBA.html#Messerli">Messerli 1998</A>).</FONT><FONT face="Verdana, Arial, Helvetica, sans-serif" size=2> 
                    </FONT></div>
                </LI>
              </ul>
              <br>
            </div>
          </td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="28" width="54"></td>
    <td valign="top"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#55C6C6">
        <tr> 
          <td width="723" height="28" bgcolor="73babd"> 
           
          </td>
        </tr>
      </table>
    </td>
  </tr>
</table>
</body>
</html>
